Reviva Proclaims Pricing of $18.0 Million Public Providing of Frequent Inventory and Warrants by Investing.com

CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) — Reviva Prescription drugs Holdings, Inc. (NASDAQ: RVPH) (Reviva or the Firm), a late-stage pharmaceutical firm growing therapies that search to deal with unmet medical wants within the areas of central nervous system (CNS), inflammatory and cardiometabolic ailments, at present introduced the pricing of an underwritten public providing of 12,000 000 shares of frequent inventory in addition to Collection A warrants to buy as much as 6,000,000 shares of frequent inventory and Collection B warrants to buy as much as 12,000,000 shares of frequent inventory. Every share of frequent inventory was offered with (i) one Collection A warrant to buy 0.5 shares of frequent inventory, and (ii) one Collection B warrant to buy one share of frequent inventory, at a mixed public providing value of $1.50. per frequent share and accompanying Collection A and B warrants. The Collection A Warrants are exercisable instantly upon issuance at an train value of $1.50 per complete share and can expire six months after the date of issuance. The Collection B Warrants are exercisable instantly upon issuance at an train value of $1.50 per share and can expire 5 years from the date of issuance. The providing is predicted to shut on or about December 18, 2024, topic to customary closing situations.

Residents JMP is appearing as sole bookrunner for the general public providing.

Reviva expects to obtain mixture gross proceeds from the general public providing of roughly $18.0 million, excluding underwriting reductions and commissions and different offering-related bills. Reviva intends to make use of the online proceeds from the providing to fund analysis and growth actions and for working capital and different basic company functions.

The securities topic to the general public providing are being supplied pursuant to a prospectus complement and the accompanying base prospectus, forming a part of a shelf registration assertion on Kind S-3 (File No. 333- 262348), which was beforehand filed with the Securities and Trade Fee. (SEC) on January 26, 2022 and have become efficient on February 2, 2022. A preliminary prospectus complement and accompanying base prospectus regarding the general public providing have been filed with the SEC and can be found at SEC net at www.sec.gov. A remaining prospectus complement regarding the general public providing will probably be filed with the SEC and will probably be obtainable on the SEC’s web site positioned at www.sec.gov. When obtainable, copies of the ultimate prospectus complement and the accompanying base prospectus could also be obtained freed from cost by contacting Residents JMP Securities, LLC, 600 Montgomery Avenue, Suite 1100, San Francisco, CA 94111, by e-mail at syndicate@jmpsecurities.com or by phone at (415) 835-8985.

This press launch doesn’t represent a proposal to promote or a solicitation of a proposal to purchase any of the securities described herein, nor shall there be any sale of those securities in any state or different jurisdiction whereby such provide, solicitation or sale could be illegal previous to registration or qualification beneath the securities legal guidelines of any such state or different jurisdiction.

About Reviva

Reviva is a late-stage biopharmaceutical firm that discovers, develops and seeks to commercialize next-generation therapeutics for ailments representing unmet medical wants and burdens to society, sufferers and their households. Reviva’s present portfolio focuses on central nervous system (CNS), inflammatory and cardiometabolic ailments. Reviva’s pipeline at present consists of two drug candidates, brilaroxazine (RP5063) and RP1208. These are two new chemical entities found internally. Reviva has been granted compositional patents for brilaroxazine and RP1208 in america, Europe and a number of other different nations.

Ahead-looking statements

This launch accommodates forward-looking statements made pursuant to the secure harbor provisions of the Non-public Securities Litigation Reform Act of 1995. These statements are usually preceded by phrases comparable to believes, expects, anticipates, intends, will, might, ought to or comparable expressions. . These forward-looking statements replicate administration’s present data, assumptions, judgments and expectations concerning future efficiency or occasions. Though administration believes that the expectations mirrored in these statements are cheap, they provide no assurance that such expectations will show to be appropriate or that these goals will probably be achieved, and you have to be conscious that precise outcomes may differ materially from these contained within the statements. forecasts. -appearance declarations. Ahead-looking statements are topic to a variety of dangers and uncertainties, together with, with out limitation, dangers related to the satisfaction of customary closing situations regarding the providing and uncertainties regarding using the product of the provide. For a extra detailed description of the dangers and uncertainties that might trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding the Firm’s enterprise usually, please discuss with the Firm’s prospectus complement. Firm required to be filed with the SEC and the paperwork included therein by reference, together with the Firm’s Kind 10-Ok for the fiscal 12 months ended December 31, 2023 and Types 10-Q for the quarters ended March 31, 2024, June September 30, 2024 and September 30, 2024.

All forward-looking statements are expressly certified of their entirety by this cautionary assertion. You’re cautioned to not place undue reliance on any forward-looking statements, which communicate solely as of the date of this launch. We’re beneath no obligation, and expressly disclaim any obligation, to replace, revise or appropriate any forward-looking statements, whether or not on account of new data, future occasions or in any other case.

Supply: Reviva Prescription drugs